secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2025-12-08T23:59:59+00:00
Accession:  0001601830-25-000174
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Recursion reports positive Phase 1b/2 data for REC-4881 in FAP: 75% show polyp burden reduction
--------------------------------------------------------------------------------

- 75% of evaluable patients reduced total polyp burden at 12 weeks; median reduction 43%.
- At 25 weeks (12 weeks off therapy), 82% maintained reduction with 53% median decrease from baseline.
- 40% of patients achieved ≥1-point improvement in Spigelman stage (upper GI disease severity).
- Safety profile consistent with MEK1/2 inhibition; no Grade ≥4 TRAEs reported to date.
- Company to engage FDA in 1H26 for registration pathway; trial expanding to ages ≥18.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183025000174/0001601830-25-000174-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183025000174/rxrx-20251208.htm
  HTML page:      https://secwatch.observer/filing/0001601830-25-000174

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer